Needham & Company Downgrades Allos Therapeutics (ALTH) to Hold; Modest Increases in FOLOTYN Sales Expected in 2011, as Company Executes Strategy May 11, 2011 08:10AM
Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference Apr 12, 2011 07:39AM
Notable 52-Week Highs and Lows of the Day 03/04: (LEI) (JNPR) (SPRD) High; (CEDC) (ALTH) Low Mar 4, 2011 02:07PM
Needham & Company Reiterates a 'Buy' on Allos Therapeutics (ALTH); Management Seeks to Drive Growth of FOLOTYN in US, Pursue Regulatory Strategy/Partnership in Europe Mar 4, 2011 08:37AM
Needham & Company Reiterates a 'Buy' on Allos Therapeutics (ALTH); FOLOTYN Sales Ramp Continues to Be Modest, Yet New Dosing Strategy and Permanent Reimbursement Code May Drive Sales in 2011 Jan 5, 2011 07:59AM


Oct 12, 2010 07:44AM Needham & Company Reiterates a 'Buy' on Allos Therapeutics (ALTH); FOLOTYN Phase 2 NSCLC Data at ESMO Congress Demonstrate Activity
Jul 28, 2010 03:39PM Notable 52-Week High's and Low's of the Day 07/28: BRCM, APL, CHRW, SIMG High; MHS, ALTH, FORM, DJSP Low
Mar 1, 2010 05:39PM After-Hours Movers 3/1: CKEC, QCOR, CVI Higher; SYKE, NTRI, PNNT, LTXC, ATSI Lower
Jan 8, 2010 10:51AM Notable Analyst Rating Changes 1/8: HAL, AMAT, JCP, AGU, ESV, RDN, More Upgraded; M, KO, STX, ERIC, WEN, PCS, More Downgraded
Oct 5, 2009 05:54PM After-Hours Movers 10/05: NTRI, CRUS, AMMD, DINE Higher; EXTR, TISI, RBN, LAD, ALTH Lower
Jul 23, 2009 10:01AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)